Immunogenicity Of Biological Drugs: Why, How And What
Recorded Webinar | Michel Awwad | From: Jun 30, 2020 - To: Dec 31, 2020
|
The consequences of an immune response to biologicals range from the transient appearance of antibodies without any clinical significance to severe life-threatening conditions. Understanding why an immune response is generated, how to detect or predict its generation will help in designing products that will be efficacious and therapeutic.
Areas Covered in the Webinar:-
In this webinar, we will discuss:
Why Should You Attend:-
The consequences of an immune response to biological drugs range from the transient appearance of antibodies without any clinical significance to severe life-threatening conditions. To develop efficacious and therapeutic biologicals, one needs to investigate the immunogenicity of these drugs, i.e. their ability to induce the generation of anti-drug antibodies, that might abrogate the efficacy of these drugs and, in a worst-case situation, might be very harmful to the patients. For this reason, Regulatory Agencies all over the world requires drug developers to have immunogenicity plan that includes mitigation steps in the event of the development of anti-drug antibodies.
Scientists involved in developing such drugs, need to be cognizant of the biochemical characteristics of their drugs and their immunogenicity potential. Moreover, they need to know how to test for the generation of an immune response and plan mitigation steps if need be.
In this webinar, we will discuss the ability of biologicals to induce the generation of an immune response against the drug itself (immunogenicity potential) and the consequences of such a response. To be able to detect the immunogenicity potential of a drug, we will discuss the need to develop assays that can specifically and reliably measure the immune response. Additionally, we will discuss the different methods used_and their caveats_to predict, a priori, the immunogenicity potential of biologicals.
Who Will Benefit:-
From